SAN CARLOS, Calif., October 19, 2026 – ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced it has secured $36 million in financing led by Catalio Capital Management, a leading innovative healthcare and AI investment firm, with continued support from Baheal, ZAP’s strategic partner in China. The financing reflects strong investor confidence in ZAP’s technology, commercial momentum, and growth potential for non-invasive robotic therapeutics throughout neuroscience.
The capital will support global expansion of the company’s ZAP-X® Gyroscopic Radiosurgery® platform to healthcare institutions across leading academic medical centers, community hospitals, and physician led practices. ZAP recently achieved a major commercial milestone with the shipment of its 50th ZAP-X system and is currently scaling its production capacity to support increasing demand globally. With nearly 10,000 patients treated worldwide, the growing body of clinical evidence continues to demonstrate the advantages of Gyroscopic Radiosurgery in treatment precision and speed for brain tumors and other neurological conditions.
“This financing reflects our conviction that ZAP Surgical is uniquely positioned to usher in a new wave of non-invasive radiosurgery globally,” said Catalio’s Nicholas von Guionneau, M.D., Ph.D., who also joins ZAP’s Board as an Observer. “With rising healthcare costs in developed nations and underserved populations in emerging markets, intelligent robotics will play an indispensable role in reducing cost structures while elevating the standard of care. ZAP’s mission to make non-invasive brain therapy broadly accessible aligns perfectly with our strategy of backing disruptive healthcare technologies.”
Beyond well-established indications in neuro-oncology, ZAP and collaborators have over the past decade demonstrated in multiple mammalian brain models the neuromodulatory effects of precisely targeted low dose ionizing radiation, now referred to as “radiomodulation”. Preliminary data was recently reported from a first-in-human pilot study evaluating patients with severe treatment resistant depression (TRD) treated with radiomodulation on the ZAP-X platform. Based on encouraging early outcomes, broader multi-center clinical trials are now being planned to treat a wide variety of psychiatric disorders beginning with TRD and addiction.
“We are delighted to welcome Catalio as a new capital partner,” said John R. Adler, M.D., Founder and CEO of ZAP Surgical Systems and Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. “As our understanding of the brain deepens, neuroscience will see unprecedented therapeutic breakthroughs over the coming decade. Scaling non-invasive, cost-effective therapy to tens of millions of patients worldwide will require strong, mission-aligned partners. Baheal has already been instrumental in advancing our presence in China and Catalio’s strategic support will be invaluable as we accelerate adoption throughout the U.S. and expand our commercial footprint.”
About ZAP Surgical Systems, Inc.:
ZAP Surgical Systems, Inc., a global leader in robotic brain surgery, is pioneering the next generation of non-invasive robotic therapeutics across neuroscience. Founded in 2014 by Dr. John R. Adler, Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University, ZAP introduced ZAP-X® Gyroscopic Radiosurgery®, the world’s first vault-free radiosurgery platform. With nearly 10,000 patients treated worldwide, ZAP continues to expand its global footprint in neuro-oncology while advancing radiomodulation, an emerging approach to treating neuropsychiatric disorders, beginning with treatment-resistant depression and addiction. Learn more at ZAP Surgical and follow us on LinkedIn.
About Catalio Capital Management, LP:
Catalio Capital Management, LP, is a New York-based investment firm focused on the full lifecycle of innovative healthcare and AI investing across private, public and credit markets with over $2 billion in assets under management.
Learn more about Catalio Capital Management by visiting www.cataliocapital.com.
Contacts:
Nikita Kulkarni
Chief Financial Officer / Investor Relations
Email: investorrelations@zapsurgical.com